NextEra to Buy Dominion; Ryanair Rallies; Regeneron Drops on Disappointing Data
Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- NextEra Energy (NEE) agreed to pay about $67 billion in stock for Dominion Energy (D) in the biggest power acquisition ever, creating a giant utility extending from Florida to the data centers clustered in Virginia. The deal would give NextEra a swathe of electricity assets stretching across Virginia and the Carolinas and position it as a dominant utility in a region that’s struggling to meet the surge in demand from newly built artificial intelligence facilities.
- Ryanair (RYAAY) gains as it delivered a decent end to the year, but flagged impact ahead from rising costs. The airline said unit costs for 2027 could increase by a mid-single digit percentage, with concerns over current unhedged jet fuel prices, and also impact from higher crew and aircraft maintenance costs.
- Regeneron Pharmaceuticals (REGN) shares drop after the drugmaker’s phase 3 data for fianlimab in metastatic melanoma fell short of expectations. Citi downgraded its rating on the stock following the “disappointing” trial update.
See omnystudio.com/listener for privacy information.
More description
Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- NextEra Energy (NEE) agreed to pay about $67 billion in stock for Dominion Energy (D) in the biggest power acquisition ever, creating a giant utility extending from Florida to the data centers clustered in Virginia. The deal would give NextEra a swathe of electricity assets stretching across Virginia and the Carolinas and position it as a dominant utility in a region that’s struggling to meet the surge in demand from newly built artificial intelligence facilities.
- Ryanair (RYAAY) gains as it delivered a decent end to the year, but flagged impact ahead from rising costs. The airline said unit costs for 2027 could increase by a mid-single digit percentage, with concerns over current unhedged jet fuel prices, and also impact from higher crew and aircraft maintenance costs.
- Regeneron Pharmaceuticals (REGN) shares drop after the drugmaker’s phase 3 data for fianlimab in metastatic melanoma fell short of expectations. Citi downgraded its rating on the stock following the “disappointing” trial update.
See omnystudio.com/listener for privacy information.
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.